Juniper Publishers-Cancer Therapy Oncology International Journal

Blinded Independent Central Imaging in Clinical Trials: Does it ensure Against Bias? Authored by Sunil Aggarwal Blinded independent central imaging reads (BICR) are compared against the local evaluation of site. In clinical trials, it has been noted that BICR have lesser bias in comparison to local evaluation. The discordance rates in central reads may still exist but its advantages over weighs the existing dis-advantages. Overall survival measurement still remains the gold standard for any compound efficacy although progression free survival measurement needs to be well documented, if a compound is so tested. There is always a potential for informative censoring with central reads. To Read More.. Full Text  in Cancer Therapy & Oncology International Journal  in Juniper Publishers

Current Standards of Systemic Therapies in Advanced Hepatocellular Cancer: A Review Authored by Piyush Vyas Sorafenib a multikinase inhibitor is the only approved systemic therapy in the treatment of advanced hepatocellular cancer. No other targeted therapy have proved to be better, a lot of phase 3 trials with many targeted have shown no significant or clinically relevant activity. After SHARP trial no other trial with any other targeted therapy has shown any significant improvement in the treatment of hepatocellular cancer. EACH trial, a phase 3 randomized trial conducted on Asian patients proved better RR and PFS of FOLFOX4 regimen when compared to doxorubicin, showed efficacy and safety of FOLFOX4 protocol. In the light of so many negative phase 3 trials with targeted therapies, it seems only sorafenib still can be considered a standard therapy in advanced HCC. To Read More.. Full Text  in Cancer Therapy & Oncology International Journal   in Juniper P